Erste Group Bank Has Weak Outlook for Roche FY2026 Earnings

Roche Holding AG (OTCMKTS:RHHBY) – Stock analysts at Erste Group Bank decreased their FY2026 EPS estimates for Roche in a research report issued to clients and investors on Thursday, June 25th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $3.12 per share for the year, down from their prior forecast of $3.18. The consensus estimate for Roche’s current full-year earnings is $3.29 per share.

Several other research firms have also issued reports on RHHBY. Argus upgraded Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Morgan Stanley raised shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price for the company in a research report on Friday, April 24th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $51.50.

Roche Price Performance

Shares of OTCMKTS:RHHBY opened at $50.32 on Thursday. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. Roche has a 12-month low of $37.51 and a 12-month high of $60.85. The business’s fifty day simple moving average is $51.19 and its 200-day simple moving average is $52.65.

Institutional Trading of Roche

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RHHBY. Confluence Investment Management LLC lifted its holdings in shares of Roche by 1.2% during the second quarter. Confluence Investment Management LLC now owns 20,925 shares of the company’s stock worth $1,074,000 after purchasing an additional 258 shares during the period. Oakworth Capital Inc. lifted its stake in shares of Roche by 20.8% in the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after purchasing an additional 285 shares during the period. Enterprise Financial Services Corp lifted its stake in shares of Roche by 6.6% in the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock valued at $277,000 after purchasing an additional 345 shares during the period. Archer Investment Corp boosted its holdings in Roche by 7.7% during the first quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock worth $278,000 after buying an additional 398 shares in the last quarter. Finally, Diversified Trust Co boosted its holdings in Roche by 0.8% during the first quarter. Diversified Trust Co now owns 59,375 shares of the company’s stock worth $2,907,000 after buying an additional 448 shares in the last quarter.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann?La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.